Dr. Robert Coleman, a member of the editorial board of OB/GYN Clinical Alert since 2004, has been elected as the next President of the Society of Gynecologic Oncologists. Congratulations to Rob as he takes over this important leadership role. Unfortunately for us, the additional duties have made it difficult to keep up with his editorial work, so Dr. Coleman has decided to step down with this month’s commentary. His insights into the complex epidemiology and treatment of gynecologic cancer will be missed. Please join me is wishing him well with his SGO Presidency and his research and clinical activities. We will miss you, Rob.
Welcome Molly Brewer, DVM, MD, as our newest Associate Editor. Dr. Brewer is Professor of Gynecologic Oncology and Chair of the Department of OB/GYN at the University of Connecticut. She completed her residency training in OB/GYN at OHSU and her oncology fellowship at MD Anderson. In addition to her interest in women’s cancer, Molly has considerable expertise and interest in medical education. Please join me in welcoming her to the editorial board of OB/GYN Clinical Alert.
A Farewell Message
It is with mixed emotions that I announce my departure from OB/GYN Clinical Alert. In serving as section contributor of gynecologic oncology for more than 10 years, I have truly enjoyed the outlet for reporting important scientific works that this periodical affords. It is unique, timely, and nimble in its format, which provides an opportunity to rapidly discuss important topics from the literature through data synthesis and context by clinical commentary. I equally enjoyed reading the contributions of my co-contributors in each issue, learning what goes on in the world of obstetrics and gynecology outside of oncology. Unfortunately, time commitments from my expanding administrative and leadership responsibilities to our professional organization, the Society of Gynecologic Oncology, has caused me to reduce my regular efforts to the Alert. While I am excited to embark on this next iteration of professional development, I will miss the collegiality of the editorial team and my co-contributors. However, I know I leave the publication in the very capable hands of my good friend and colleague, Dr. Molly Brewer. Molly is one of the smartest and most insightful people I know, and I look forward to her stewardship of the oncology section. I would also like to commend the professionalism and kindness of the editorial team and my many co-contributors over the years — it’s been an honor to server with you and I wish you the best of success. RLC
